Skip Navigation


NDT Advance Access originally published online on February 15, 2008
Nephrology Dialysis Transplantation 2008 23(7):2129-2132; doi:10.1093/ndt/gfn029
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/7/2129    most recent
gfn029v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daniel, L.
Right arrow Articles by Dignat-George, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daniel, L.
Right arrow Articles by Dignat-George, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Circulating microparticles in renal diseases

Laurent Daniel1,2, Laetitia Dou3, Yvon Berland4, Philippe Lesavre5, Lise Mecarelli-Halbwachs5 and Francoise Dignat-George3,6

1 Department of Pathology, CHU Timone-Adultes 2 UMR 911 INSERM, Université de la Méditerranée 3 UMR-S 608 INSERM, Université de la Méditerranée 4 Department of Nephrology, CHU Conception, Marseille 5 Department of Nephrology, CHU Necker and INSERM 507, Paris 6 Department of Haematology, CHU Conception, Marseille, France

Correspondence and offprint requests to: Laurent Daniel, Hopital Timone - Anatomo-Pathologie 264 rue st-pierre Marseille 13005, France. Tel: +334-9138-5531; Fax: +334-9138-4411; E-mail: laurent.daniel{at}ap-hm.fr

Keywords: atherosclerosis; microparticles; renal failure; vasculitis



   Introduction
Top
 Introduction
Conclusion
 References
 
Cellular microparticles (MP) are submicrometric fragments resulting from the remodelling of the plasma membrane in response to numerous conditions, including activation and apoptosis [1]. The general consensus is that MP are small (<1 µm), expose the anionic phospholipid phosphatidylserine (PhtdSer) and express membrane antigens that reflect their cellular origin. These characteristics discriminate MP from exosomes, which are smaller (<0.1 µm), originate from intracellular multivesicular bodies and differ in antigenic composition [2].

MP formation, composition and functions
All cell types shed MP according to an active process controlling plasma membrane remodelling and antigenic turnover. Among the mechanisms proposed, disruption of the natural asymmetric distribution of membrane phospholipids is thought to be an important step explaining the translocation of PhtdSer to the exoplasmic leaflet before membrane blebbing and MP shedding. Although calcium entry, activation of calpains and scramblase activity have been reported to be important processes [3], the exact mechanisms governing MP formation are not completely understood.

MP phospholipid composition, phenotypes and content vary according to the cellular origin and the inducer triggering their formation (Table 1). Determination of the cellular origin of MP relies on the expression of specific antigens. According to the cell type, their formation occurs following exposure to various agents, including calcium ionophore, ATP depletion, lipopolysaccharides, thrombin, cytokines and autoantibodies (Table 1). Therefore, vesiculation is a well-regulated process generating MP that present specific features, with significant implications on their functional activity.


View this table:
[in this window]
[in a new window]

  		Table 1 MP cell origin and antigenic features

 
Indeed, MP behave as vectors of bioactive molecules able to disseminate biological information in the vascular compartment. Due to the expression of both membrane PhtdSer and functional tissue factor (TF), MP are catalytic procoagulant surfaces involved in thrombogenesis. They also harbour inflammatory components (LpA, IL-1 and chemokine receptor CCR5) [4,5], growth factors (TGF-beta and VEGF) and proteases (uPA and MMP) that are related to their involvement in inflammation, immune response, angiogenesis and cancer [6–8].

MP measurement and variations in atherosclerotic vascular diseases
Different methodologies, which were reported in a forum [9], are available for MP determination. Antibody-capture ELISA and flow cytometry rely on the antigenic composition of MP and allow them to be enumerated according to their cellular origin. Besides, functional assays measuring MP-associated procoagulant activity are based on PhtdSer and TF expression. Finally, other assays combine ELISA capture on annexin or antibody and determination of procoagulant activity of MP.

MP are detectable in the peripheral blood of healthy volunteers. Elevated levels of circulating platelet-, monocyte- or endothelial-derived MP have been reported in cardiovascular disorders such as diabetes [10], acute coronary syndromes, hypertension [11], metabolic syndrome, heart transplantation and pulmonary or venous embolism [12]. It is now obvious that MP levels are associated with cardiovascular risk factors and most often correlate with disease severity and clinical outcome [1].

MP in renal diseases
Elevated levels of MP have been detected throughout the entire process of vascular damage associated with renal diseases.

During renal diseases with acute vascular lesions, such as Wegener granulomatosis or micro-polyangiitis, MP originating from platelets and neutrophils increase dramatically. These levels, which were significantly higher than those reported in chronic vasculitis, may be considered as markers of disease activity [13]. In children with acute vasculitis, increased levels of endothelial MP (EMP) correlated with the Birmingham Vasculitis Activity Score and the acute-phase reactant levels, suggesting that they could be used as diagnostic tool in the context of febrile diseases [14].

A vesiculation process, reflecting endothelial injury and platelet activation, is also a feature of vascular disorders associated with immune-mediated renal lesions. In agreement, high platelet MP (PMP) levels are observed in microangiopathies, whereas EMP vary as lactate dehydrogenase levels over the course of acute phase. Elevation of EMP has also been reported in antiphospholipid syndrome, where they strongly correlate with procoagulant activity of lupus anticoagulant [15].

MP levels are increased during chronic renal failure (CRF), suggesting that vesiculation may participate in thrombogenesis and compensation for the bleeding tendency in CRF. Elevated PMP counts have been reported in CRF patients (pre-dialyzed, under haemodialysis and under ambulatory peritoneal dialysis), with significantly higher levels in patients with thrombotic events. The existence of an arteriovenous fistula did not affect PMP count [16]. It is well established that CRF patients display accelerated atherosclerosis related to endothelial dysfunction. Hence, high EMP levels, detected in uraemic patients in the absence of a clinical history of vascular disease, may constitute an early indicator of vascular injury [17].

Diabetes is a confounding factor during CRF, but PMP levels are equivalent during end-stage CRF whatever be the initial diseases, i.e. diabetic nephropathies or others. Additionally, the increase in EMP levels in series remains significant after exclusion of diabetic patients. Finally, among diabetic patients, PMP and EMP levels are higher in those presenting nephropathies [18].

High PMP levels are clearly a risk factor for thrombotic events in non-CRF patients. Although it is well known that the main drugs used for cardiovascular diseases and CRF are able to decrease MP number and procoagulant activity, one should also keep in mind that they have not been evaluated in the main series. This is particularly true for statins [19] and nifedipine [20], which decrease, respectively, leukocyte-platelet MP and PMP.

In patients with end-stage CRF, platelet, erythrocyte, and endothelial MP are increased [21]. However, only EMP levels correlate with a loss of flow-mediated dilatation and increased aortic pulse wave velocity, suggesting that they are highly associated with arterial and endothelial dysfunction in end-stage CRF [22].

MP are both causes and consequences of vascular dysfunction (Figure 1)
In acute vascular lesions, numerous in vitro studies have accounted for a direct role of MP in disease progression. Renal microvessel cells exposed to plasma of patients with thombotic thrombopenic purpura shed prothrombotic MP expressing von Willebrand Factor (VWF) that can spread into the circulation of the ultralarge VWF multimers resulting from ADAMTS-13 deficiency. In immune-mediated acquired renal disease, MP bear procoagulant activity detected in patients with antiphospholipid syndrome. MP may be pathogenic when they bear proteinase 3, as in antineutrophil cytoplasmic antibody (ANCA)-vasculitis [15].


Figure 1
View larger version (39K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 This schema summarizes the concept that MP are both causes and consequences of vascular dysfunction. Pl, platelets; PMN, polymorphonuclear cells; Mo, monocytes; MP, microparticles; AGEs, advanced glycation end products.

 
In patients with CRF, EMP levels may reflect subclinical lesions because their levels correlate with arterial stiffness and vasodilatation changes [21]. In this context, MP could also participate in the progression of vascular lesions because a decrease in endothelial nitric oxide is detected in vitro when EMP from uraemic patients are added on rodent aorta rings in culture.

Besides endothelial-dependent vasodilatation changes, other vascular abnormalities reflected by the alteration of VWF and thrombomodulin concentrations have been correlated with MP levels in CRF. Increased PMP levels may be a crucial step for arteriosclerosis, because PMP promote chemokine Rantes deposits on endothelial cells and favour leukocyte recruitment, particularly, in the context of pre-existing atherosclerosis as in CRF [23].

In patients with CRF, one could speculate that the initial stimuli that lead to MP generation could result from a release of LPS, AGEs, proinflammatory cytokines (TNF{alpha} and IL-1) or oxidized LDL, reflecting the oxidant stress. Uraemic toxins might also be involved because para-cresol and indoxyl sulphate induce vesiculation by HUVEC (human umbilical vein endothelial cell) [17].

Haemodialysis treatment is among the stimuli inducing MP generation. A dramatic increase in PMP is observed at the end of a dialysis session. This is probably explained by the membrane-induced complement activation and biological effects of extracorporeal dialysers. Results are not similar for EMP. As dialysis restores viscosity, which is reflected by haematocrit, it also restores laminar shear stress and thus may decrease EMP levels, because it is well known that a lower local shear stress is associated with endothelial apoptosis and MP release [21]. The complement is another factor of vesiculation, since a membrane attack complex is formed during the first minutes of dialysis. Nevertheless, the membrane type (synthetic or celluloid) has no significant effect on circulating MP levels [13]. Another cause for MP release is the endotoxins present in the dialysate fluid.



   Conclusion
Top
 Introduction
 Conclusion
References
 
MP behave as effectors that play a deleterious role in renal diseases. They also represent novel biomarkers that are useful to appreciate cardiovascular risk associated with CRF and sometimes disease activity. The pharmacological control of MP is the next challenge in the control of CRF-vascular complications.

Conflict of interest statement. None declared.



   References
Top
 Introduction
 Conclusion
 References
 

  1. Freyssinet JM, Dignat-George F. More on: measuring circulating cell-derived microparticles. J Thromb Haemost (2005) 3:613–614.[CrossRef][Web of Science][Medline]
  2. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood (1999) 94:3791–3799.[Abstract/Free Full Text]
  3. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev (2006) 20:1–26.[CrossRef][Web of Science][Medline]
  4. Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med (2000) 6:769–775.[CrossRef][Web of Science][Medline]
  5. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity (2001) 15:825–835.[CrossRef][Web of Science][Medline]
  6. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood (2004) 104:2543–2548.[Abstract/Free Full Text]
  7. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol (2006) 26:2594–2604.[Abstract/Free Full Text]
  8. Mezentsev A, Merks RM, O’Riordan E, et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol (2005) 289:1106–1114.[CrossRef]
  9. Jy W, Horstman LL, Jimenez JJ, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2:1842–1851.[CrossRef][Web of Science][Medline]
  10. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes (2002) 51:2840–2845.[Abstract/Free Full Text]
  11. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension (2003) 4:211–217.
  12. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension (2006) 48:180–186.[Free Full Text]
  13. Daniel L, Fakhouri F, Joly D, et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int (2006) 69:1416–1423.[Web of Science][Medline]
  14. Brogan PA, Shah V, Brachet C, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum (2004) 50:927–936.[CrossRef][Web of Science][Medline]
  15. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. J Thromb Haemost (2004) 91:667–673.
  16. Ando M, Iwata A, Ozeki Y, et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int (2002) 62:1757–1763.[CrossRef][Web of Science][Medline]
  17. Faure V, Dou L, Sabatier F, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost (2006) 4:566–573.[CrossRef][Web of Science][Medline]
  18. Omoto S, Nomura S, Shouzu A, et al. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia (2002) 45:550–555.[CrossRef][Web of Science][Medline]
  19. Nomura S, Shouzu A, Omoto S, et al. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis (2004) 18:177–185.[CrossRef][Web of Science][Medline]
  20. Nomura S, Shouzu A, Omoto S, et al. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res (2005) 115:277–285.[CrossRef][Web of Science][Medline]
  21. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 16:3381–3388.[Abstract/Free Full Text]
  22. Boulanger CM, Amabile N, Guerin AP, et al. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension (2007) 49:902–908.[Abstract/Free Full Text]
  23. Mause SF, von Hundelshausen P, Zernecke A, et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol (2005) 25:1512–1518.[Abstract/Free Full Text]
  24. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood (1999) 93:3451–3456.[Abstract/Free Full Text]
  25. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol (1994) 153:3245–3255.[Abstract]
  26. Watanabe J, Marathe GK, Neilsen PO, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem (2003) 278:33161–33168.[Abstract/Free Full Text]
  27. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation (2004) 109:1653–1659.[Abstract/Free Full Text]
  28. Combes V, Dignat-George F, Mutin M, et al. A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. J Thromb Haemost (1997) 77:220.
  29. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest (1999) 104:93–102.[Web of Science][Medline]
Received for publication: 25. 6.07
Accepted in revised form: 16. 1.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/7/2129    most recent
gfn029v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daniel, L.
Right arrow Articles by Dignat-George, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daniel, L.
Right arrow Articles by Dignat-George, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?